We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App





Pfizer to Seek FDA Emergency Use Authorization for Its COVID-19 Vaccine in Late November

By HospiMedica International staff writers
Posted on 19 Oct 2020
Print article
Illustration
Illustration
The first COVID-19 vaccine could be considered for Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) by November.

In an open letter, Albert Bourla, chief executive officer of Pfizer Inc. (New York, NY, USA), has stated that the company will submit efficacy and safety data for its vaccine candidate BNT-162 being developed in partnership with Biopharmaceutical New Technologies (BioNTech Mainz, Germany) to the FDA for EUA after the third week of November. Bourla stated that in order to seek approval for public use, it must be proved that the COVID-19 vaccine is effective, safe and can be consistently manufactured at the highest quality standards. Pfizer expects to know whether or not its COVID-19 vaccine candidate is effective towards the end of October by when there will be a certain number of COVID-19 cases in its trial for comparing the effectiveness of its vaccine in vaccinated individuals against participants who have been given a placebo.

The decision to apply for EUA for its COVID-19 vaccine candidate ‘soon after’ a safety milestone is reached in the third week of November will ensure that Pfizer complies with the FDA’s recent COVID-19 vaccine development guidance that requires developers to provide safety data from at least half its trial patients taken two months following the final vaccine dose. Following the achievement of a positive efficacy readout and a robust safety profile, Pfizer will finally submit manufacturing data that demonstrates the quality and consistency of its COVID-19 vaccine that will be produced.

“So let me be clear, assuming positive data, Pfizer will apply for Emergency Authorization Use in the US soon after the safety milestone is achieved in the third week of November,” wrote Bourla.

Related Links:
Pfizer Inc.
Biopharmaceutical New Technologies


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Hydrogen Peroxide Sterilizer
HMA-30

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Surgical Techniques

view channel
Image: NTT and Olympus have begun the world\'s first joint demonstration experiment of a cloud endoscopy system (Photo courtesy of Olympus)

Cloud Endoscopy System Enables Real-Time Image Processing on the Cloud

Endoscopes, which are flexible tubes inserted into the body's natural openings for internal examination and biopsy collection, are becoming increasingly vital in medical diagnostics. Their minimal invasiveness... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.